28.7 C
New York
Friday, June 12, 2026

Tag: weight

Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working...

Revenue increased 449% year-over-year while the Company continued to scale its healthcare infrastructure platform. VANCOUVER, BC and LAS VEGAS, June 1, 2026 /CNW/ - Hydreight...

ZHITAI at COMPUTEX: Targeting Gamers and High-Performance Creators with Flagship SSD Launches Across the APAC Region

TAIPEI, June 2, 2026 /PRNewswire/ -- As the global SSD market welcomes a new era of diverse choices, ZHITAI, the consumer memory brand under YMTC,...

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)  announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

HIMS IMPORTANT DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before...

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

Best Plumbing Contractor Business Loans: ROK Financial Expands No Credit Check Financing Access for Companies Facing Credit Challenges

Plumbing contractors in 2025 across the United States face rising costs, tighter lending standards, and limited access to traditional credit. ROK Financial’s expansion of no credit check business loan programs responds to growing demand for flexible financing, offering contractors new pathways to secure working capital and sustain growth despite credit challenges.
Plumbing contractors in 2025 across the United States face rising costs, tighter lending standards, and limited access to traditional credit. ROK Financial’s expansion of no credit check business loan programs responds to growing demand for flexible financing, offering contractors new pathways to secure working capital and sustain growth despite credit challenges.

Best Pool and Spa Construction Business Loans for Bad Credit: ROK Financial Expands No Credit Check Financing Options Ahead of 2025 Season

ROK Financial announces new loan pathways for pool and spa contractors heading into the 2025 season. By offering no credit check financing, fast approvals, and expanded loan ranges, the company addresses growing demand among small business owners with fair or poor credit histories. This initiative responds to the sharp rise in alternative lending searches and the increased pressure on contractors seeking reliable capital access as traditional banks tighten standards.
ROK Financial announces new loan pathways for pool and spa contractors heading into the 2025 season. By offering no credit check financing, fast approvals, and expanded loan ranges, the company addresses growing demand among small business owners with fair or poor credit histories. This initiative responds to the sharp rise in alternative lending searches and the increased pressure on contractors seeking reliable capital access as traditional banks tighten standards.

Best No Credit Check Business Financing Demand Rises as ROK Financial Expands Access to Small Business Loans in 2025

The best no credit check business financing options in 2025 are gaining momentum as small business owners face tighter traditional lending standards and rising uncertainty in the economy. ROK Financial is meeting this demand with flexible loan programs, instant pre-approvals, and expanded access to capital for entrepreneurs across industries. By offering a range of solutions — from working capital and SBA loans to equipment and real estate financing — the company reflects a larger movement toward credit-independent funding that aligns with modern business needs.
The best no credit check business financing options in 2025 are gaining momentum as small business owners face tighter traditional lending standards and rising uncertainty in the economy. ROK Financial is meeting this demand with flexible loan programs, instant pre-approvals, and expanded access to capital for entrepreneurs across industries. By offering a range of solutions — from working capital and SBA loans to equipment and real estate financing — the company reflects a larger movement toward credit-independent funding that aligns with modern business needs.

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

Hims & Hers (HIMS) Drops Amid Reported Details of FTC Investigation, Adding To Investor Scrutiny In Pending Securities Class Action – Hagens Berman

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- On August 14, 2025 the price of Hims & Hers Health (NYSE: HIMS) shares significantly dropped in after-hours trading after the financial press reported that the FTC is probing the company’s advertising practices and whether it makes it too difficult for customers to cancel subscriptions.

Announcing the Karma Gyesera, a Potent Performance Grande Coupé Packing Razor-Sharp Design, Luxurious Refinement and Low-Volume Exclusivity for Drivers Seeking to Jettison the Ordinary

Breaking Cover at Monterey Car Week 2025, the Hybrid EREV Gyesera Begins Production in Q4/2025 and is the Long-Awaited Successor to the Innovative Revero MONTEREY, Calif.,...

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

Best Ergonomic Office Chair for Long Hours (2025): FlexiSpot C7 Max Recognized as Top Comfort & Support Choice by Expert Consumers

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Expert Consumers has recognized the FlexiSpot C7 Max as the Best Ergonomic Office Chair for Long Hours...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH

HIMS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsWeight